

Cover Story
Conversation with The Cancer Letter
By Jacquelyn Cobb, Matthew Bin Han Ong and Paul Goldberg
The past six weeks have brought fundamental change in the way oncology drugs are being developed. At this unprecedented moment in oncopolitics, FDA, NCI, academic oncologists, advocates, and the industry are in agreement on how cancer therapies should be developed, tested and approved.
In Brief


Clinical Roundup


Trending Stories
- Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight
NCI to remain intact, but its finances are uncertain; FDA is spared big cuts - John Burklow replaced by Seana Cranston as NIH chief of staff
- In the Headlines: What’s in Trump’s draft budget?
- NCI summarizes changes to the CCSG NOFO
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - AACR announces 2025 Scientific Achievement Award recipients